ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Goserelin

Also written as “Goserelin acetate”, “ZOLADEX” and “Inj. Goserelin (Test) Subcutaneously”.

Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms · Metrorrhagia, led by 4 companies.

Drug pageGoserelin: every studyAll 103 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 26, 200512 company-led studies, 1 open or runningNext primary completion: Mar 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only80 open or runningphase 4since Oct 26, 2005Oct 10, 2005none ahead
Eurofarma Laboratoriosits history only20 open or runningphase 3since Apr 29, 2019Apr 29, 2019none ahead
Peptigroupeits history only10 open or runningphase 1since Jun 9, 2020Jun 9, 2020none ahead
TerSera Therapeutics11 open or runningphase 1since Dec 16, 2025Dec 16, 2025Mar 30, 2027phase 1 · NCT07310420

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of TerSera Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT07310420 · 176 planned · United States

Ahead

  1. Mar 30, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07310420

TargetBeta

GNRH1 →GNRHR →read by rule
“A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
triptorelinruleIpsenphase 421

Studies

The one study TerSera Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07310420Breast Neoplasms · United States1RecruitingMar 30, 2027176

How it is read

Names in the registry

  • “Goserelin acetate”, 5 entries
  • “Goserelin”, 2 entries
  • “ZOLADEX”, 1 entry
  • “Inj. Goserelin (Test) Subcutaneously”, 1 entry
  • “Goserelin acetate 3.6 mg Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.